Total Funding
83
94
Total FundingGrant raised
Growth Score
-1 pts
Heat Score
24 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
13634
Lys Therapeutics develops drugs to treat patients suffering from neurovascular or neurodegenerative disorders.
- Guillaume Lebel: Active ShareholderPast Role: J2V Capital, Co-Founder
- Philippe Dujardin: CFO and Co-Founder
About the Company
Lys Therapeutics is a biotechnology company developing drugs to treat patients suffering from neurovascular or neurodegenerative disorders. The company's main drug is a monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action, that triggers off-target toxicity through hyperactivation of both vascular and
neuronal NMDA receptors (NMDAr). It causes the disruption of the blood-brain and blood-spinal cord barriers and strong neuronal excitotoxicity including stroke and multiple sclerosis.
